Pharmaxis Appoints Spanish Distributor for Aridol

SYDNEY, Australia, Jan. 22 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced the appointment of Aldo-Union SA to market and distribute its asthma diagnostic and management tool, Aridol, in Spain. Spain is among the first group of countries selected to review the Aridol marketing application as part of the European Union Mutual Recognition Procedure expected to conclude during the first quarter of 2007.

Dr Alan Robertson, Pharmaxis CEO said: "Spain is a key market and we are delighted to announce our agreement with Aldo-Union, a respiratory specialist pharmaceutical company with a long heritage in inhaled medicines for asthma. Aldo-Union's strong reputation in respiratory medicine and its broad coverage of the domestic territory with its own sales force, make it the ideal partner for Pharmaxis to introduce and develop the Spanish market for Aridol."

Dr Josep Sabater, Managing Director of Aldo-Union said: "Since its establishment in the early sixties, Aldo-Union has been devoted to developing, producing and marketing inhaled drugs for treating obstructive diseases of the respiratory system. As a local leader in the respiratory field, Aridol fits perfectly within our product portfolio. It is a unique product that will enable us to strengthen and widen our commitment to asthma patients from the very beginning of their symptoms.

"Aridol is a valuable contribution to asthma management. We are strongly convinced that this partnering between Pharmaxis and Aldo-Union will make a major contribution to improving asthmatics' quality of life."

The total Spanish population affected by asthma is estimated to be approximately 2.7 million people. The bronchial challenge testing market is dominated by methacholine and is one of few European markets where testing to assess effectiveness of treatment is performed. Following Aridol's approval by Swedish authorities, Pharmaxis lodged its application for marketing approval for a further 13 countries under the EU Mutual Recognition Procedure in December. Spain is among the first group of 13 countries scheduled to register Aridol.

To find out more about Pharmaxis, go to http://www.pharmaxis.com.au .

For more information about Pharmaxis, Aridol or Aldo-Union, see http://www.pharmaxis.com.au/library/2007_01_22_Aridol_distributor_Spain.pdf

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

CONTACT:

Alan Robertson -- Pharmaxis Chief Executive Officer

Tel: +61-2-9454-7202

Fax: +61-2-9451-3622

Website: www.pharmaxis.com.au

Released through:

United States:

Brandon Lewis, Trout Group

Tel: +1-212-477-9007

Email: blewis@troutgroup.com

Australia:

Virginia Nicholls

Tel: +61-417-610-824

Email: virginia.nicholls@pharmaxis.com.au